{
    "abstract": "Objective: Vaccination of infants against hepatitis B virus (HBV) using hepatitis B vaccine is effective in preventing the infection during early childhood and there is a growing evidence of long-term protection. So far, no need for a booster dose has been identified in healthy subjects; however further follow-up continues to determine the exact duration of protection. We evaluated antibody persistence and immune response to a hepatitis B vaccine challenge dose in children aged 15-16 years, previously vaccinated with 3-doses of the same vaccine in infancy (third dose received before 18 months of age). Methods: A single hepatitis B vaccine challenge dose containing 10 \u03bcg hepatitis B surface (HBs) antigen was administered to adolescents aged 15-16 years. Blood samples were taken before and one month after the challenge dose to measure anti-HBs antibodies using a chemiluminescence immunoassay. Solicited local and general symptoms, as well as unsolicited and serious adverse events were recorded after the challenge dose. Results: 303 subjects were enrolled, of whom 302 and 293 subjects formed the total vaccinated and according-to-protocol cohorts, respectively. Pre-challenge, 65.4% (95% CI: 59.6-70.9) subjects were seroprotected (anti-HBs antibody concentration \u226510 mIU/mL). One month post-challenge, 97.9% (95% CI: 95.6-99.2) were seroprotected, while 90.8% (95% CI: 86.8-93.8) had anti-HBs antibody concentrations \u2265100 mIU/mL. The post-challenge geometric mean concentration (GMC; 4134.9 [95% CI: 3114.2-5490.1]) was 150-fold higher than the pre-challenge GMC. Overall, 96.9% (95% CI: 94.2-98.6) subjects mounted an anamnestic response. The safety and reactogenicity profile of the hepatitis B vaccine challenge dose was consistent with previous experience. Conclusions: Immunity to hepatitis B persists in 15-16 year old adolescents following primary vaccination in infancy. Trial registration: http://www.clinicaltrials.gov NCT01847430.",
    "bib_entries": {
        "bib0125": {
            "authors": [
                {
                    "first": "Aparna",
                    "initial": "A.",
                    "last": "Schweitzer"
                },
                {
                    "first": "Johannes",
                    "initial": "J.",
                    "last": "Horn"
                },
                {
                    "first": "Rafael T.",
                    "initial": "R.T.",
                    "last": "Mikolajczyk"
                },
                {
                    "first": "G\u00e9rard",
                    "initial": "G.",
                    "last": "Krause"
                },
                {
                    "first": "J\u00f6rdis J.",
                    "initial": "J.J.",
                    "last": "Ott"
                }
            ],
            "doi": "10.1016/S0140-6736(15)61412-X",
            "firstpage": "1546",
            "issn": "01406736",
            "lastpage": "1555",
            "pmid": "26231459",
            "pub_year": 2015,
            "title": "Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013",
            "volume": "386"
        },
        "bib0130": {
            "authors": [
                {
                    "first": "Adrian",
                    "initial": "A.",
                    "last": "Cassidy"
                },
                {
                    "first": "Sally",
                    "initial": "S.",
                    "last": "Mossman"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Olivieri"
                },
                {
                    "first": "Marc De",
                    "initial": "M.D.",
                    "last": "Ridder"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                }
            ],
            "doi": "10.1586/erv.11.151",
            "firstpage": "1709",
            "issn": "14760584",
            "lastpage": "1715",
            "pmid": "22085174",
            "pub_year": 2011,
            "title": "Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity",
            "volume": "10"
        },
        "bib0135": {
            "authors": [
                {
                    "first": "Alessandro R.",
                    "initial": "A.R.",
                    "last": "Zanetti"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Shouval"
                }
            ],
            "doi": "10.1016/j.vaccine.2008.09.056",
            "firstpage": "6266",
            "issn": "0264410X",
            "lastpage": "6273",
            "pmid": "18848855",
            "pub_year": 2008,
            "title": "The global impact of vaccination against hepatitis B: A historical overview",
            "volume": "26"
        },
        "bib0140": null,
        "bib0145": null,
        "bib0150": {
            "authors": [
                {
                    "first": "Karl",
                    "initial": "K.",
                    "last": "Schenkel"
                },
                {
                    "first": "Doris",
                    "initial": "D.",
                    "last": "Radun"
                },
                {
                    "first": "Viviane",
                    "initial": "V.",
                    "last": "Bremer"
                },
                {
                    "first": "Nikolaus",
                    "initial": "N.",
                    "last": "Bocter"
                },
                {
                    "first": "Osamah",
                    "initial": "O.",
                    "last": "Hamouda"
                }
            ],
            "doi": "10.1186/1471-2458-8-132",
            "issn": "14712458",
            "pmid": "18433490",
            "pub_year": 2008,
            "title": "Viral hepatitis in Germany: Poor vaccination coverage and little knowledge about transmission in target groups",
            "volume": "8"
        },
        "bib0155": {
            "authors": [
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Behre"
                },
                {
                    "first": "Gerhard",
                    "initial": "G.",
                    "last": "Bleckmann"
                },
                {
                    "first": "Priya Diana",
                    "initial": "P.D.",
                    "last": "Crasta"
                },
                {
                    "first": "Maarten",
                    "initial": "M.",
                    "last": "Leyssen"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Messier"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Jacquet"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Hardt"
                }
            ],
            "doi": "10.4161/hv.19898",
            "firstpage": "813",
            "issn": "2164554X",
            "lastpage": "818",
            "pmid": "22508412",
            "pub_year": 2012,
            "title": "Long-term anti-HBs antibody persistence and immune memory in children and adolescents who received routine childhood hepatitis B vaccination",
            "volume": "8"
        },
        "bib0160": {
            "authors": [
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Roznovsky"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Orsagova"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Kloudova"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Tvrdik"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Kabieszova"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Lochman"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Mrazek"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Hozakova"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Zjevikova"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Pliskova"
                }
            ],
            "doi": "10.1007/s15010-010-0039-7",
            "firstpage": "395",
            "issn": "03008126",
            "lastpage": "400",
            "pmid": "20589522",
            "pub_year": 2010,
            "title": "Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up",
            "volume": "38"
        },
        "bib0165": {
            "authors": [
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Duval"
                },
                {
                    "first": "Vladimir",
                    "initial": "V.",
                    "last": "G\u00eelca"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Boulianne"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "De Wals"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Mass\u00e9"
                },
                {
                    "first": "Gisele",
                    "initial": "G.",
                    "last": "Trudeau"
                },
                {
                    "first": "Gaston",
                    "initial": "G.",
                    "last": "De Serres"
                }
            ],
            "doi": "10.1097/01.inf.0000154329.00361.39",
            "firstpage": "213",
            "issn": "08913668",
            "lastpage": "218",
            "pmid": "15750456",
            "pub_year": 2005,
            "title": "Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country",
            "volume": "24"
        },
        "bib0170": {
            "authors": [
                {
                    "first": "Jangu E.",
                    "initial": "J.E.",
                    "last": "Banatvala"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Van Damme"
                }
            ],
            "doi": "10.1046/j.1365-2893.2003.00400.x",
            "firstpage": "1",
            "issn": "13520504",
            "lastpage": "6",
            "pmid": "12558904",
            "pub_year": 2003,
            "title": "Hepatitis B vaccine - Do we need boosters?",
            "volume": "10"
        },
        "bib0175": null,
        "bib0180": {
            "authors": [
                {
                    "first": "Marianne A.B.",
                    "initial": "M.A.B.",
                    "last": "Van Der Sande"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Waight"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Mendy"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Rayco-Solon"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Hutt"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Fulford"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Doherty"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "McConkey"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Jeffries"
                },
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Hall"
                },
                {
                    "first": "H. C.",
                    "initial": "H.C.",
                    "last": "Whittle"
                }
            ],
            "doi": "10.1086/503433",
            "firstpage": "1528",
            "issn": "00221899",
            "lastpage": "1535",
            "pmid": "16652281",
            "pub_year": 2006,
            "title": "Long-term protection against carriage of hepatitis B virus after infant vaccination",
            "volume": "193"
        },
        "bib0185": {
            "authors": [
                {
                    "first": "Jalal",
                    "initial": "J.",
                    "last": "Poorolajal"
                },
                {
                    "first": "Mahmood",
                    "initial": "M.",
                    "last": "Mahmoodi"
                },
                {
                    "first": "Reza",
                    "initial": "R.",
                    "last": "Majdzadeh"
                },
                {
                    "first": "Siavosh",
                    "initial": "S.",
                    "last": "Nasseri-Moghaddam"
                },
                {
                    "first": "Ali Akbar",
                    "initial": "A.A.",
                    "last": "Haghdoost"
                },
                {
                    "first": "Akbar",
                    "initial": "A.",
                    "last": "Fotouhi"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.10.068",
            "firstpage": "623",
            "issn": "0264410X",
            "lastpage": "631",
            "pmid": "19887132",
            "pub_year": 2010,
            "title": "Long-term protection provided by hepatitis B vaccine and need for booster dose: A meta-analysis",
            "volume": "28"
        },
        "bib0190": {
            "authors": [
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Koen",
                    "initial": "K.",
                    "last": "Van Herck"
                }
            ],
            "doi": "10.1016/j.tmaid.2006.04.004",
            "firstpage": "79",
            "issn": "14778939",
            "lastpage": "84",
            "pmid": "17298912",
            "pub_year": 2007,
            "title": "A review of the long-term protection after hepatitis A and B vaccination",
            "volume": "5"
        },
        "bib0195": {
            "authors": [
                {
                    "first": "Eric E.",
                    "initial": "E.E.",
                    "last": "Mast"
                },
                {
                    "first": "Cindy M.",
                    "initial": "C.M.",
                    "last": "Weinbaum"
                },
                {
                    "first": "Anthony E.",
                    "initial": "A.E.",
                    "last": "Fiore"
                },
                {
                    "first": "Miriam J.",
                    "initial": "M.J.",
                    "last": "Alter"
                },
                {
                    "first": "Beth P.",
                    "initial": "B.P.",
                    "last": "Bell"
                },
                {
                    "first": "Lyn",
                    "initial": "L.",
                    "last": "Finelli"
                },
                {
                    "first": "Lance E.",
                    "initial": "L.E.",
                    "last": "Rodewald"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "Douglas"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Janssen"
                },
                {
                    "first": "John W.",
                    "initial": "J.W.",
                    "last": "Ward"
                }
            ],
            "firstpage": "1",
            "issn": "15458601",
            "lastpage": "CE1",
            "pmid": "17159833",
            "pub_year": 2006,
            "title": "A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults.",
            "volume": "55"
        },
        "bib0200": {
            "authors": [
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Moiseeva"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Marichev"
                },
                {
                    "first": "Anne Diane",
                    "initial": "A.D.",
                    "last": "Kervyn"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Booy"
                },
                {
                    "first": "Sherine",
                    "initial": "S.",
                    "last": "Kuriyakose"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Brockway"
                },
                {
                    "first": "Su Peing",
                    "initial": "S.P.",
                    "last": "Ng"
                },
                {
                    "first": "Maarten",
                    "initial": "M.",
                    "last": "Leyssen"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Jacquet"
                }
            ],
            "doi": "10.1186/1471-2334-10-357",
            "issn": "14712334",
            "pmid": "21171982",
            "pub_year": 2010,
            "title": "Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: A randomised controlled study",
            "volume": "10"
        },
        "bib0205": {
            "authors": [
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Zinke"
                },
                {
                    "first": "Rudolf",
                    "initial": "R.",
                    "last": "Kappes"
                },
                {
                    "first": "Klaus",
                    "initial": "K.",
                    "last": "Kindler"
                },
                {
                    "first": "Anke",
                    "initial": "A.",
                    "last": "Paulus-Koschik"
                },
                {
                    "first": "Uwe",
                    "initial": "U.",
                    "last": "Goering"
                },
                {
                    "first": "Johann",
                    "initial": "J.",
                    "last": "Disselhoff"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Soemantri"
                },
                {
                    "first": "Detlef",
                    "initial": "D.",
                    "last": "Grunert"
                },
                {
                    "first": "Karl Heinz",
                    "initial": "K.H.",
                    "last": "Laakmann"
                },
                {
                    "first": "Ramakrishnan",
                    "initial": "R.",
                    "last": "Gunasekaran"
                },
                {
                    "first": "Britta",
                    "initial": "B.",
                    "last": "Gartner"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Jacquet"
                }
            ],
            "doi": "10.4161/hv.9051",
            "firstpage": "592",
            "issn": "15548600",
            "lastpage": "598",
            "pmid": "19535920",
            "pub_year": 2009,
            "title": "Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine",
            "volume": "5"
        },
        "bib0210": {
            "authors": [
                {
                    "first": "Yong",
                    "initial": "Y.",
                    "last": "Poovorawan"
                },
                {
                    "first": "Voranush",
                    "initial": "V.",
                    "last": "Chongsrisawat"
                },
                {
                    "first": "Apiradee",
                    "initial": "A.",
                    "last": "Theamboonlers"
                },
                {
                    "first": "Hans L.",
                    "initial": "H.L.",
                    "last": "Bock"
                },
                {
                    "first": "Maarten",
                    "initial": "M.",
                    "last": "Leyssen"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Jacquet"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.10.074",
            "firstpage": "730",
            "issn": "0264410X",
            "lastpage": "736",
            "pmid": "19892043",
            "pub_year": 2010,
            "title": "Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand",
            "volume": "28"
        },
        "bib0215": {
            "authors": [
                {
                    "first": "Yong",
                    "initial": "Y.",
                    "last": "Poovorawan"
                },
                {
                    "first": "Voranush",
                    "initial": "V.",
                    "last": "Chongsrisawat"
                },
                {
                    "first": "Apiradee",
                    "initial": "A.",
                    "last": "Theamboonlers"
                },
                {
                    "first": "Priya Diana",
                    "initial": "P.D.",
                    "last": "Crasta"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Messier"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Hardt"
                }
            ],
            "doi": "10.4161/hv.24844",
            "firstpage": "1679",
            "issn": "21645515",
            "lastpage": "1684",
            "pmid": "23732904",
            "pub_year": 2013,
            "title": "Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: A 20-year follow-up study in Thailand",
            "volume": "9"
        },
        "bib0220": {
            "authors": [
                {
                    "first": "Vladimir",
                    "initial": "V.",
                    "last": "Gilca"
                },
                {
                    "first": "Gaston",
                    "initial": "G.",
                    "last": "De Serres"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Boulianne"
                },
                {
                    "first": "Donald",
                    "initial": "D.",
                    "last": "Murphy"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "De Wals"
                },
                {
                    "first": "Manale",
                    "initial": "M.",
                    "last": "Ouakki"
                },
                {
                    "first": "Gisele",
                    "initial": "G.",
                    "last": "Trudeau"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Mass\u00e9"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Dionne"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.037",
            "firstpage": "448",
            "issn": "0264410X",
            "lastpage": "451",
            "pmid": "23206974",
            "pub_year": 2013,
            "title": "Antibody persistence and the effect of a booster dose given 5, 10 or 15years after vaccinating preadolescents with a recombinant hepatitis B vaccine",
            "volume": "31"
        },
        "bib0225": {
            "authors": [
                {
                    "first": "Vladimir",
                    "initial": "V.",
                    "last": "Gilca"
                },
                {
                    "first": "Gaston",
                    "initial": "G.",
                    "last": "De Serres"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Boulianne"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "De Wals"
                },
                {
                    "first": "Donald",
                    "initial": "D.",
                    "last": "Murphy"
                },
                {
                    "first": "Gisele",
                    "initial": "G.",
                    "last": "Trudeau"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Mass\u00e9"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Duval"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.07.100",
            "firstpage": "6048",
            "issn": "0264410X",
            "lastpage": "6053",
            "pmid": "19683086",
            "pub_year": 2009,
            "title": "Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later",
            "volume": "27"
        },
        "bib0230": {
            "authors": [
                {
                    "first": "Olivier Der",
                    "initial": "O.D.",
                    "last": "Van Meeren"
                },
                {
                    "first": "Gerhard",
                    "initial": "G.",
                    "last": "Bleckmann"
                },
                {
                    "first": "Priya D.",
                    "initial": "P.D.",
                    "last": "Crasta"
                }
            ],
            "doi": "10.4161/hv.28480",
            "firstpage": "1682",
            "issn": "21645515",
            "lastpage": "1687",
            "pmid": "24637296",
            "pub_year": 2014,
            "title": "Immune memory to hepatitis B persists in children aged 7-8 years, who were vaccinated in infancy with 4 doses of hexavalent DTPa-HBV-IPV/Hib (Infanrix\u2122 hexa) vaccine",
            "volume": "10"
        },
        "bib0235": {
            "authors": [],
            "doi": "10.1016/j.vaccine.2009.10.110",
            "firstpage": "589",
            "issn": "0264410X",
            "lastpage": "590",
            "pmid": "19896455",
            "pub_year": 2010,
            "title": "Hepatitis B vaccines: WHO position paper-Recommendations",
            "volume": "28"
        },
        "bib0240": {
            "authors": [],
            "firstpage": "255",
            "issn": "00498114",
            "lastpage": "263",
            "pmid": "2004154422",
            "pub_year": 2004,
            "title": "Hepatitis B vaccines.",
            "volume": "79"
        }
    },
    "body_text": [
        {
            "endOffset": 15762,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "The mean age of subjects was 15.3 years (standard deviation [SD]: 0.5 years); 53.6% subjects were male and the majority (98.6%) were Caucasian/European.",
            "startOffset": 15610,
            "title": "Demographics"
        },
        {
            "endOffset": 18888,
            "parents": [],
            "refoffsets": {
                "bib0155": {
                    "endOffset": 18887,
                    "startOffset": 18878
                },
                "bib0200": {
                    "endOffset": 18887,
                    "startOffset": 18878
                },
                "bib0205": {
                    "endOffset": 18887,
                    "startOffset": 18878
                },
                "bib0210": {
                    "endOffset": 18887,
                    "startOffset": 18878
                },
                "bib0215": {
                    "endOffset": 18887,
                    "startOffset": 18878
                },
                "bib0220": {
                    "endOffset": 18887,
                    "startOffset": 18878
                }
            },
            "secId": "sec0060",
            "sentence": "Various independent long-term follow-up trials have assessed long-term antibody persistence and responses to challenge doses 5 to 20 years after a 3-dose primary vaccination course of hepatitis B vaccine in the first year of life [7,16\u201320].",
            "startOffset": 18648,
            "title": "Discussion"
        },
        {
            "endOffset": 14454,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "Although anti-HBs \u226510 mIU/mL is the most relevant cut-off, validated as a correlate of clinical protection, the primary endpoint of the study was the percentage of subjects with anti-HBs \u2265100 mIU/mL one month after the challenge dose.",
            "startOffset": 14220,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 10402,
            "parents": [],
            "refoffsets": {
                "bib0135": {
                    "endOffset": 10316,
                    "startOffset": 10308
                },
                "bib0155": {
                    "endOffset": 10316,
                    "startOffset": 10308
                },
                "bib0160": {
                    "endOffset": 10316,
                    "startOffset": 10308
                },
                "bib0165": {
                    "endOffset": 10316,
                    "startOffset": 10308
                },
                "bib0170": {
                    "endOffset": 10401,
                    "startOffset": 10394
                },
                "bib0175": {
                    "endOffset": 10401,
                    "startOffset": 10394
                },
                "bib0180": {
                    "endOffset": 10401,
                    "startOffset": 10394
                },
                "bib0185": {
                    "endOffset": 10401,
                    "startOffset": 10394
                }
            },
            "secId": "sec0005",
            "sentence": "The long-term immunogenicity induced by 3 doses of hepatitis B vaccine is well established [3,7\u201310], however, studies are on-going to determine the exact duration of protection [10\u201313].",
            "startOffset": 10217,
            "title": "Introduction"
        },
        {
            "endOffset": 17867,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "During the 31-day post vaccination follow-up period, 15.2% (95% CI: 11.4\u201319.8) subjects reported \u22651 unsolicited AE.",
            "startOffset": 17752,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 11685,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "The study was conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helsinki, and the protocol and associated documents were reviewed and approved by local ethics committees.",
            "startOffset": 11479,
            "title": "Study design and subjects"
        },
        {
            "endOffset": 17412,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "The challenge dose was generally well-tolerated.",
            "startOffset": 17364,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 20504,
            "parents": [],
            "refoffsets": {
                "bib0155": {
                    "endOffset": 20503,
                    "startOffset": 20500
                }
            },
            "secId": "sec0060",
            "sentence": "Moreover, these results are in line with previous experience where 99.6% and 97.2% of subjects aged 7\u20138 and 12\u201313 years of age, respectively, mounted an anamnestic response after a challenge dose [7].",
            "startOffset": 20304,
            "title": "Discussion"
        },
        {
            "endOffset": 19726,
            "parents": [],
            "refoffsets": {
                "bib0225": {
                    "endOffset": 19582,
                    "startOffset": 19578
                }
            },
            "secId": "sec0060",
            "sentence": "These observations are in line with results from Canada [21], another country of low endemicity, where 85% of subjects remained seroprotected 10 years after 3-dose hepatitis B vaccine primary vaccination.",
            "startOffset": 19522,
            "title": "Discussion"
        },
        {
            "endOffset": 16704,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "One month post-challenge, the percentage of seroprotected subjects increased to 97.9% (95% CI: 95.6\u201399.2) and 90.8% (95% CI: 86.8\u201393.8) had anti-HBs antibody concentrations \u2265100 mIU/mL (Table 1).",
            "startOffset": 16509,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 21442,
            "parents": [],
            "secId": "sec0060",
            "sentence": "None of them presented with anti-HBc, suggesting that they had not developed hepatitis B infection at any point in the past.",
            "startOffset": 21318,
            "title": "Discussion"
        },
        {
            "endOffset": 21676,
            "parents": [],
            "secId": "sec0060",
            "sentence": "Three subjects failed to demonstrate an anamnestic response while their pre-challenge titre was >100 mIU/mL, indicative the persistence of protection; we hypothesize that a \u201csaturation effect\u201d could explain this outlying observation.",
            "startOffset": 21443,
            "title": "Discussion"
        },
        {
            "endOffset": 22426,
            "parents": [],
            "secId": "sec0060",
            "sentence": "Although different studies in various settings have demonstrated the long-term protection offered by hepatitis B vaccine, the necessity of a booster dose still remains unanswered.",
            "startOffset": 22247,
            "title": "Discussion"
        },
        {
            "endOffset": 16167,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "They were eliminated from the ATP analysis on the ground that contact with the wild virus could have boosted their immunity, which would bias the analysis of immune persistence.",
            "startOffset": 15990,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 12039,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Healthy adolescents aged 15\u201316 years who had received three doses of monovalent paediatric hepatitis B vaccine (containing 10 \u03bcg hepatitis B surface antigen, HBsAg) in infancy (third dose received before 18 months of age), as part of routine clinical practice, were enrolled.",
            "startOffset": 11764,
            "title": "Study design and subjects"
        },
        {
            "endOffset": 15218,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "Safety analyses were performed on the total vaccinated cohort (TVC) which included all subjects who received the vaccination according to the protocol.",
            "startOffset": 15067,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 16860,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "An anamnestic response was observed in 96.9% (95% CI: 94.2\u201398.6) subjects.",
            "startOffset": 16786,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 16509,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "The anti-HBs antibody GMC was 26.5 mIU/mL (95% CI: 21.4\u201332.8).",
            "startOffset": 16447,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 15989,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "The medical record of those subjects revealed no evidence of past hepatitis B infection.",
            "startOffset": 15901,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 9765,
            "parents": [],
            "refoffsets": {
                "bib0130": {
                    "endOffset": 9764,
                    "startOffset": 9759
                },
                "bib0135": {
                    "endOffset": 9764,
                    "startOffset": 9759
                }
            },
            "secId": "sec0005",
            "sentence": "Vaccination is the most effective way to reduce the incidence of hepatitis B and infection, and is particularly successful when infants are targeted [2,3].",
            "startOffset": 9610,
            "title": "Introduction"
        },
        {
            "endOffset": 21199,
            "parents": [],
            "secId": "sec0060",
            "sentence": "In our study, nine subjects failed to invoke an anamnestic response, of whom six (2%) were considered unprotected before and after the challenge dose.",
            "startOffset": 21049,
            "title": "Discussion"
        },
        {
            "endOffset": 13777,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Solicited local (pain, redness, swelling) and general symptoms (fatigue, gastrointestinal symptoms, headache and fever) occurring during the 4-day follow-up period, and unsolicited adverse events (AEs) occurring within 31 days of the challenge dose, were recorded using diary cards.",
            "startOffset": 13495,
            "title": "Safety analyses"
        },
        {
            "endOffset": 21883,
            "parents": [],
            "secId": "sec0060",
            "sentence": "As the subjects included in our study received primary Hepatitis B vaccination as part of routine clinical practice, data on the immune response after completion of the primary vaccination are not available.",
            "startOffset": 21676,
            "title": "Discussion"
        },
        {
            "endOffset": 9954,
            "parents": [],
            "refoffsets": {
                "bib0140": {
                    "endOffset": 9910,
                    "startOffset": 9907
                },
                "bib0145": {
                    "endOffset": 9953,
                    "startOffset": 9950
                }
            },
            "secId": "sec0005",
            "sentence": "Since 1991, the World Health Organization (WHO) has recommended the inclusion of hepatitis B vaccination in national immunization programmes [4] and so far 183 countries have complied [5].",
            "startOffset": 9766,
            "title": "Introduction"
        },
        {
            "endOffset": 19521,
            "parents": [],
            "refoffsets": {
                "bib0155": {
                    "endOffset": 19465,
                    "startOffset": 19462
                }
            },
            "secId": "sec0060",
            "sentence": "As expected, this is slightly lower than previous studies conducted in Germany, where seroprotection rates of 83.3% and 78.3% were reported after 5 and 10 years of primary vaccination, respectively [7], and reflects natural waning of circulating antibodies.",
            "startOffset": 19264,
            "title": "Discussion"
        },
        {
            "endOffset": 20803,
            "parents": [],
            "refoffsets": {
                "bib0230": {
                    "endOffset": 20802,
                    "startOffset": 20798
                }
            },
            "secId": "sec0060",
            "sentence": "Similar data are available from Germany for individuals primed with the combination vaccine Infanrix hexa\u2122 (GSK Vaccines, Belgium), which contains the hepatitis B vaccine component in combination with vaccines against diphtheria, tetanus, acellular pertussis, polio and Haemophilus influenzae [22].",
            "startOffset": 20505,
            "title": "Discussion"
        },
        {
            "endOffset": 22247,
            "parents": [],
            "secId": "sec0060",
            "sentence": "In particular, we are not able to confirm whether non-responders to the challenge dose had responded or not to their primary immunization course.",
            "startOffset": 22102,
            "title": "Discussion"
        },
        {
            "endOffset": 21049,
            "parents": [],
            "refoffsets": {
                "bib0215": {
                    "endOffset": 21048,
                    "startOffset": 21044
                }
            },
            "secId": "sec0060",
            "sentence": "The ability to mount an anamnestic response upon hepatitis B vaccine challenge remains \u226596% even 20 years after primary vaccination, demonstrating that persistence of immune memory outlasts the presence of detectable circulating antibodies [19].",
            "startOffset": 20804,
            "title": "Discussion"
        },
        {
            "endOffset": 10873,
            "parents": [],
            "refoffsets": {
                "bib0155": {
                    "endOffset": 10872,
                    "startOffset": 10869
                }
            },
            "secId": "sec0005",
            "sentence": "Persistent immunity and robust immune responses to hepatitis B vaccine challenge doses have been reported in Germany in children aged 7\u20138 and 12\u201313 years, 5 and 10 years post-primary hepatitis B vaccination, respectively [7].",
            "startOffset": 10648,
            "title": "Introduction"
        },
        {
            "endOffset": 12997,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Seropositivity was defined as anti-HBs antibody concentration \u22656.2 mIU/mL and seroprotection as \u226510 mIU/mL.",
            "startOffset": 12890,
            "title": "Immunogenicity analyses"
        },
        {
            "endOffset": 15067,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "The immunogenicity analyses were performed on the according-to-protocol (ATP) cohort for immunogenicity, comprising all vaccinated subjects who met the eligibility criteria, complied with protocol-defined procedures and for whom data concerning the immunogenicity endpoint measures were available at the post-vaccination time point.",
            "startOffset": 14735,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 10217,
            "parents": [],
            "refoffsets": {
                "bib0150": {
                    "endOffset": 10067,
                    "startOffset": 10064
                },
                "bib0155": {
                    "endOffset": 10216,
                    "startOffset": 10213
                }
            },
            "secId": "sec0005",
            "sentence": "From 1995, when Germany first included the hepatitis B vaccine in the national routine immunization program, [6] until 2001, routine infant vaccination has been administered as 3 doses of monovalent recombinant hepatitis B vaccine in the first years of life [7].",
            "startOffset": 9955,
            "title": "Introduction"
        },
        {
            "endOffset": 19263,
            "parents": [],
            "secId": "sec0060",
            "sentence": "Approximately fifteen years after primary vaccination with paediatric monovalent hepatitis B vaccine according to the local recommendations (at age 2 months, 4 months, and 11\u201314 months), 65.4% subjects remained seroprotected against hepatitis B in the current study.",
            "startOffset": 18997,
            "title": "Discussion"
        },
        {
            "endOffset": 14056,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "Serious adverse events (SAEs) were recorded during the entire study period.",
            "startOffset": 13981,
            "title": "Safety analyses"
        },
        {
            "endOffset": 14735,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "All the objectives of the study were descriptive.",
            "startOffset": 14686,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 23006,
            "parents": [],
            "secId": "sec0060",
            "sentence": "Our results confirm that paediatric doses of hepatitis B vaccine confer long-term protection against hepatitis B in adolescents up to 15\u201316 years, and produce robust immune memory.",
            "startOffset": 22826,
            "title": "Discussion"
        },
        {
            "endOffset": 12794,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Blood samples were collected before and one month after the challenge dose and were analyzed for anti-HBs antibody concentrations using a chemiluminescence immunoassay (CLIA).",
            "startOffset": 12619,
            "title": "Immunogenicity analyses"
        },
        {
            "endOffset": 18426,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Two subjects recorded SAEs (lower limb fracture and arthralgia), of which neither was considered to be related to vaccination.",
            "startOffset": 18300,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 11171,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "This was a phase-IV, open-label, non-randomized study conducted at 10 centres in Germany between July 2013 and February 2014 (NCT01847430).",
            "startOffset": 11032,
            "title": "Study design and subjects"
        },
        {
            "endOffset": 22101,
            "parents": [],
            "secId": "sec0060",
            "sentence": "No comparisons can therefore be made between the immune response observed immediately after primary vaccination with those observed at the end of long-term follow-up period and poses the main limitation of this study.",
            "startOffset": 21884,
            "title": "Discussion"
        },
        {
            "endOffset": 20303,
            "parents": [],
            "refoffsets": {
                "bib0175": {
                    "endOffset": 20302,
                    "startOffset": 20298
                }
            },
            "secId": "sec0060",
            "sentence": "This confirms that maintaining anti-HBs antibody concentrations >10 mIU/mL may not be essential for protection against clinically significant breakthrough hepatitis B infection [11].",
            "startOffset": 20121,
            "title": "Discussion"
        },
        {
            "endOffset": 15900,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Two subjects were found positive for anti-HBc antibodies, suggesting they had been in contact with the hepatitis B virus.",
            "startOffset": 15779,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 18067,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Any grade 3 unsolicited AE was recorded in five subjects (1.7%) and comprised vertigo, streptococcal infection, lower limb fracture, migraine, tremor and dysmenorrhoea, each in an individual subject.",
            "startOffset": 17868,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 16786,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "GMCs rose to 4134.9 mIU/mL (95% CI: 3114.2\u20135490.1), an increase of over 150-fold.",
            "startOffset": 16705,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 22768,
            "parents": [],
            "refoffsets": {
                "bib0175": {
                    "endOffset": 22607,
                    "startOffset": 22603
                },
                "bib0235": {
                    "endOffset": 22545,
                    "startOffset": 22538
                },
                "bib0240": {
                    "endOffset": 22545,
                    "startOffset": 22538
                }
            },
            "secId": "sec0060",
            "sentence": "However, results from our study, as well as from other long-term follow-up studies support the proposal of WHO [23,24] and the European Consensus Group on Hepatitis B Immunity [11] that booster vaccination of healthy individuals after primary hepatitis B vaccination in infancy is not recommended, at least for the first 15\u201320 years of life.",
            "startOffset": 22427,
            "title": "Discussion"
        },
        {
            "endOffset": 20120,
            "parents": [],
            "secId": "sec0060",
            "sentence": "Despite declining levels of circulating anti-HBs antibodies, the vast majority of subjects in our study were able to mount a rapid and robust anamnestic response after a challenge dose (more than 150-fold increase in GMC) regardless of their pre-challenge serostatus.",
            "startOffset": 19853,
            "title": "Discussion"
        },
        {
            "endOffset": 15346,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "Statistical analyses were performed using Statistical Analysis System (SAS) versions 9.2 on SDD (SAS drug development software).",
            "startOffset": 15218,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 12215,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Subjects who had received any additional HBV booster vaccination since primary vaccination, or presented with a history of hepatitis B infection, were excluded from the study.",
            "startOffset": 12040,
            "title": "Study design and subjects"
        },
        {
            "endOffset": 17336,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Stratifying according to pre-challenge dose serostatus, 92.9% subjects with pre-challenge anti-HBs antibody levels <6.2 mIU/mL, all those with levels \u22656.2\u2013<10 mIU/mL and 98.4% with levels \u226510 mIU/mL mounted an anamnestic response to the Hepatitis B vaccine challenge (Table 2).",
            "startOffset": 17059,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 16446,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "While 71.2% (95% CI: 65.7\u201376.4) were seropositive (anti-HBs antibodies \u22656.2 mIU/mL) before the challenge dose, 65.4% (95% CI: 59.6\u201370.9) remained seroprotected (anti-HBs antibodies \u226510 mIU/mL).",
            "startOffset": 16253,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 10982,
            "parents": [],
            "secId": "sec0005",
            "sentence": "This current study reports the long term persistence of hepatitis B vaccine in adolescents aged 15\u201316 years.",
            "startOffset": 10874,
            "title": "Introduction"
        },
        {
            "endOffset": 18299,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "These symptoms were injection site reactions (n = 4, including redness [1] and swelling [1]), and dizziness (n = 1).",
            "startOffset": 18183,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 13363,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Anamnestic responses to a challenge dose were also measured; where an anamnestic response was defined as \u22654-fold increase in anti-HBs antibody concentration post-challenge in subjects who were seropositive before receiving the challenge dose, or post-challenge anti-HBs antibody concentration \u226510 mIU/mL in subjects seronegative before receiving the challenge dose.",
            "startOffset": 12998,
            "title": "Immunogenicity analyses"
        },
        {
            "endOffset": 13477,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Antibodies against hepatitis B core antigen (HBc) were determined using enzyme linked immunosorbent assay (ELISA).",
            "startOffset": 13363,
            "title": "Immunogenicity analyses"
        },
        {
            "endOffset": 22826,
            "parents": [],
            "secId": "sec0060",
            "sentence": "Future studies may ultimately further extend this period.",
            "startOffset": 22769,
            "title": "Discussion"
        },
        {
            "endOffset": 14219,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "The primary endpoint of the study was the percentage of subjects with anti-HBs antibody concentrations \u2265100 mIU/mL one month post-challenge.",
            "startOffset": 14079,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 17752,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "Injection site pain (26.8% [95% CI: 21.9\u201332.2]) and fatigue (27.8% [95% CI: 22.8\u201333.2]) were the most frequently reported solicited local and general symptoms, respectively; they were also the most frequently reported grade 3 symptoms in their respective categories (0.3% [95% CI: 0\u20131.8] and 2.6% [95% CI: 1.2\u20135.2], respectively) (Fig. 2).",
            "startOffset": 17413,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 23095,
            "parents": [],
            "secId": "sec0065",
            "sentence": "Engerix-B Kinder and Infanrix hexa are trademarks of the GSK group of companies.",
            "startOffset": 23015,
            "title": "Trademark"
        },
        {
            "endOffset": 9492,
            "parents": [],
            "refoffsets": {
                "bib0125": {
                    "endOffset": 9491,
                    "startOffset": 9488
                }
            },
            "secId": "sec0005",
            "sentence": "Hepatitis B infection is a serious global public health problem and is a major cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma [1].",
            "startOffset": 9341,
            "title": "Introduction"
        },
        {
            "endOffset": 12889,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Geometric mean concentrations (GMCs) were calculated with exact 95% confidence intervals (CI).",
            "startOffset": 12795,
            "title": "Immunogenicity analyses"
        },
        {
            "endOffset": 15609,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "Nine subjects were excluded from the ATP cohort for immunogenicity (Fig. 1).",
            "startOffset": 15533,
            "title": "Demographics"
        },
        {
            "endOffset": 13980,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0030",
            "sentence": "The intensity of AEs was graded on a 3-point scale where Grade 3 was defined as: any symptom preventing normal daily activities; fever: axillary temperature >39 \u00b0C; redness or swelling: diameter >50 mm.",
            "startOffset": 13778,
            "title": "Safety analyses"
        },
        {
            "endOffset": 19853,
            "parents": [],
            "refoffsets": {
                "bib0210": {
                    "endOffset": 19852,
                    "startOffset": 19845
                },
                "bib0215": {
                    "endOffset": 19852,
                    "startOffset": 19845
                }
            },
            "secId": "sec0060",
            "sentence": "Two studies from Thailand reported that around 60% subjects remained seroprotected 20 years after primary vaccination [18,19].",
            "startOffset": 19727,
            "title": "Discussion"
        },
        {
            "endOffset": 18182,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0055",
            "sentence": "At least one unsolicited AE, considered by the investigator to be vaccine-related, was recorded in three subjects.",
            "startOffset": 18068,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 12474,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Subjects were vaccinated with a single dose of monovalent paediatric hepatitis B vaccine containing 10 \u03bcg of HBsAg (Engerix\u2122-B Kinder; GSK Vaccines, Belgium; Lot AHBVC059A; expiry 28/02/2014) approximately 15 years after primary vaccination.",
            "startOffset": 12233,
            "title": "Vaccine details"
        },
        {
            "endOffset": 18997,
            "parents": [],
            "secId": "sec0060",
            "sentence": "This current study assessed long-term antibody persistence and immune memory in 15\u201316 years old adolescents.",
            "startOffset": 18889,
            "title": "Discussion"
        },
        {
            "endOffset": 10647,
            "parents": [],
            "refoffsets": {
                "bib0190": {
                    "endOffset": 10646,
                    "startOffset": 10642
                }
            },
            "secId": "sec0005",
            "sentence": "Further, as the majority of individuals mount strong anamnestic responses on exposure to HBV many years after priming, even in the absence of detectable circulating anti-HBs antibodies, the need for booster dosing remains under discussion [14].",
            "startOffset": 10403,
            "title": "Introduction"
        },
        {
            "endOffset": 9609,
            "parents": [],
            "refoffsets": {
                "bib0130": {
                    "endOffset": 9608,
                    "startOffset": 9605
                }
            },
            "secId": "sec0005",
            "sentence": "Approximately one-third of the world's population is estimated to have been infected by hepatitis B virus (HBV) [2].",
            "startOffset": 9493,
            "title": "Introduction"
        },
        {
            "endOffset": 11764,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Written informed consent was obtained from parents/guardians before enrolment.",
            "startOffset": 11686,
            "title": "Study design and subjects"
        },
        {
            "endOffset": 14685,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0035",
            "sentence": "We defined our primary endpoint using this more conservative cut-off to ensure that our study would have a sufficient sample size to accurately describe the percentage that was expected to be the lowest, i.e. anti-HBs \u2265100 mIU/mL.",
            "startOffset": 14455,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 16252,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Immunogenicity results were available for 292 of the 293 subjects comprising the ATP.",
            "startOffset": 16167,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 18647,
            "parents": [],
            "refoffsets": {
                "bib0195": {
                    "endOffset": 18510,
                    "startOffset": 18506
                }
            },
            "secId": "sec0060",
            "sentence": "As rates of new infection and acute disease are highest among adults [15], it is important that long-term protection, in terms of antibody persistence and ability to mount an anamnestic response, is maintained.",
            "startOffset": 18437,
            "title": "Discussion"
        },
        {
            "endOffset": 17058,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Nine subjects failed to mount a response; three of these subjects still presented anti-HBs antibodies \u2265100 mIU/mL, while six (2%) had antibody levels <10 mIU/mL before and after the challenge dose.",
            "startOffset": 16861,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 12593,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "The vaccine was administered as a 0.5 mL intramuscular injection in the deltoid muscle using a needle 25 mm in length.",
            "startOffset": 12475,
            "title": "Vaccine details"
        },
        {
            "endOffset": 21317,
            "parents": [],
            "refoffsets": {
                "bib0210": {
                    "endOffset": 21316,
                    "startOffset": 21309
                },
                "bib0215": {
                    "endOffset": 21316,
                    "startOffset": 21309
                }
            },
            "secId": "sec0060",
            "sentence": "This percentage is in line with the expected percentage of non-response following infant primary vaccination [18,19].",
            "startOffset": 21200,
            "title": "Discussion"
        },
        {
            "endOffset": 15533,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "303 subjects were enrolled and vaccinated, of whom 302 comprised the TVC; one subject was excluded from the analysis for not following the informed consent process.",
            "startOffset": 15369,
            "title": "Demographics"
        },
        {
            "endOffset": 11479,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib0155": {
                    "endOffset": 11478,
                    "startOffset": 11475
                }
            },
            "secId": "sec0015",
            "sentence": "This is the final study in a series of three, aimed at measuring the long-term persistence of hepatitis B antibodies and the ability of the immune system to mount an anamnestic response to a challenge dose of the vaccine in different age groups (age 7\u20138 years: NCT00519649 and 12\u201313 years: NCT00984139) [7].",
            "startOffset": 11172,
            "title": "Study design and subjects"
        }
    ],
    "docId": "S0264410X16301426",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "olivier.x.van-der-meeren@gsk.com",
                "first": "Olivier",
                "initial": "O.",
                "last": "Van Der Meeren"
            },
            {
                "email": null,
                "first": "Ulrich",
                "initial": "U.",
                "last": "Behre"
            },
            {
                "email": null,
                "first": "Priya",
                "initial": "P.",
                "last": "Crasta"
            }
        ],
        "doi": "10.1016/j.vaccine.2016.04.013",
        "firstpage": "2745",
        "issn": "0264410X",
        "keywords": [
            "Adolescence",
            "Anamnestic response",
            "Anti-HBs",
            "Challenge dose",
            "Hepatitis B",
            "Immune memory",
            "Long-term persistence"
        ],
        "lastpage": "2749",
        "openaccess": "Full",
        "pub_year": 2016,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunity to hepatitis B persists in adolescents 15-16 years of age vaccinated in infancy with three doses of hepatitis B vaccine"
    }
}